In silico design of Mycobacterium tuberculosis epitope ensemble vaccines

Preksha Shah, Jaymisha Mistry, Pedro A. Reche, Derek Gatherer, Darren R Flower

Research output: Contribution to journalArticlepeer-review


Effective control of Mycobacterium tuberculosis is a global necessity. In 2015, tuberculosis (TB) caused more deaths than HIV. Considering the increasing prevalence of multi-drug resistant forms of M. tuberculosis, the need for effective TB vaccines becomes imperative. Currently, the only licensed TB vaccine is Bacillus Calmette-Guérin (BCG). Yet, BCG has many drawbacks limiting its efficacy and applicability. We applied advanced computational procedures to derive a universal TB vaccine and one targeting East Africa. Our approach selects an optimal set of highly conserved, experimentally validated epitopes, with high projected population coverage (PPC). Through rigorous data analysis, five different potential vaccine combinations were selected each with PPC above 80% for East Africa and above 90% for the World. Two potential vaccines only contained CD8+ epitopes, while the others included both CD4+ and CD8+ epitopes. Our prime vaccine candidate was a putative seven-epitope ensemble comprising: SRGWSLIKSVRLGNA, KPRIITLTMNPALDI, AAHKGLMNIALAISA, FPAGGSTGSL, MLLAVTVSL, QSSFYSDW and KMRCGAPRY, with a 97.4% global PPC and a 92.7% East African PPC.
Original languageEnglish
Pages (from-to)56-62
JournalMolecular Immunology
Early online date19 Mar 2018
Publication statusPublished - May 2018

Bibliographical note

© 2018, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.

Funding: BIO2014:54164-R; Inmunotek S.L.


  • Tuberculosis
  • Vaccine
  • Immunoinformatics


Dive into the research topics of 'In silico design of Mycobacterium tuberculosis epitope ensemble vaccines'. Together they form a unique fingerprint.

Cite this